Resmetirom for treatment of MASH.
Cell
; 187(12): 2897-2897.e1, 2024 Jun 06.
Article
em En
| MEDLINE
| ID: mdl-38848671
ABSTRACT
Resmetirom is an oral selective THR-ß agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piridazinas
/
Uracila
/
Cirrose Hepática
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Cell
Ano de publicação:
2024
Tipo de documento:
Article